We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Metabolon Appoints Chief Scientific Officer

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Metabolon, Inc. has announced the addition of Dr. Michael Milburn as its Chief Scientific Officer.  Dr. Milburn was most recently Senior Vice President of Research and Corporate Development at Sirtris Pharmaceuticals
“Mike's extensive background and proven leadership ability in drug discovery and development will be valuable as we continue our biomarker discovery projects and expand our business interest into various phases of product development,” said Dr. John Ryals, president and CEO of Metabolon.
Dr. Milburn brings 15 years of experience in biotech and pharmaceutical companies to Metabolon. At Sirtris, he led the preclinical/clinical development of projects in the areas of metabolic disease and neurodegeneration. 

Prior to Sirtris, Dr. Milburn was Senior Vice President of Research at Plexxikon, where he was responsible for the development of the company's proprietary high-throughput co-crystallography drug discovery platform. 

He has also held positions at Structural Genomix and GlaxoSmithKline.  Dr. Milburn received his Ph.D. in Structural Chemistry at the University of California, Berkeley, and was a Research Fellow at Harvard Medical School for his postdoctoral work.
“Metabolon is the leading company in the development and application of metabolomics, and I look forward to building on its success,” said Dr. Milburn. 

“Metabolon's ability to identify all of the human metabolites within a disease context or drug effect represents a fast path to identifying new disease diagnostics or alternative therapeutic uses for drug candidates.”